Work

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Figure S1. Mean pharmacokinetic profiles for single agent talazoparib (BMN673 in phase I clinical trial PRP-001) versus combination therapy.

DOI: 10.1158/1078-0432.22488366

Authors: Zev A. Wainberg, Arun S. Singh, Gottfried E. Konecny, Kelly E. McCann, J. Randolph Hecht, Jonathan Goldman, Bartosz Chmielowski, Richard S. Finn, Neil O'Brien, Erika Von Euw, Megan M. Price, Diego Martinez, Lisa Yonemoto, Meghan Brennan, John A. Glaspy, Dennis J. Slamon

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361962822

Cites:

Cited by:

Related to: 10